Tempest Therapeutics AI Stock Analysis
Want to see TPST full AI Analyst Report?
Tempest Therapeutics (TPST) AI Stock Analysis
Tempest Therapeutics
(NASDAQ:TPST)
Overall score is driven primarily by weak financial performance (no revenue, continued losses and cash burn, and negative equity in TTM). Technicals add further pressure with a clear downtrend and negative momentum despite oversold readings. Corporate events provide some offset via pipeline and strategic progress, but are tempered by Nasdaq bid-price compliance risk; valuation remains unattractive/uninformative due to losses and no dividend.
Tempest Therapeutics (TPST) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.83M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.56M
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.74
- Revenue Growth
- ―
- EPS Growth
- 61.31%
- Country
- US
- Employees
- 4
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Tempest Therapeutics Business Overview & Revenue Model
Company Description
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a co...
Tempest Therapeutics Financial Statement Overview
Summary
Weak development-stage financial profile: no revenue in the periods provided, persistent large losses (TTM net loss -$40.6M) and ongoing cash burn (TTM operating/FCF about -$21.5M). Balance sheet risk is elevated with stockholders’ equity turning negative in TTM (-$1.8M) and a shrinking asset base, despite lower total debt versus prior years.
Income Statement
12Very NegativeBalance Sheet
18Very NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -22.24M | 0 | -389.00K | 0 | 0 | 0 |
| EBITDA | -39.55M | -25.79M | -40.14M | -27.66M | -33.45M | -26.65M |
| Net Income | -40.59M | -26.26M | -41.84M | -29.49M | -35.71M | -28.30M |
Balance Sheet | ||||||
| Total Assets | 8.76M | 16.93M | 41.49M | 51.60M | 46.09M | 73.24M |
| Cash, Cash Equivalents and Short-Term Investments | 897.00K | 7.71M | 30.27M | 39.23M | 31.23M | 51.83M |
| Total Debt | 7.26M | 8.14M | 15.37M | 20.66M | 22.11M | 18.54M |
| Total Liabilities | 10.59M | 10.26M | 22.36M | 24.84M | 27.98M | 37.12M |
| Stockholders Equity | -1.83M | 6.67M | 19.13M | 26.77M | 18.11M | 36.12M |
Cash Flow | ||||||
| Free Cash Flow | -21.55M | -26.82M | -33.46M | -27.53M | -31.63M | -26.09M |
| Operating Cash Flow | -21.55M | -26.82M | -33.03M | -27.36M | -31.07M | -25.96M |
| Investing Cash Flow | 0 | 0 | -435.00K | -170.00K | -562.00K | -97.00K |
| Financing Cash Flow | 9.39M | 4.26M | 24.50M | 35.60M | 11.40M | 59.06M |
Tempest Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TPST, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.67, and below the 200-day MA of 1.37, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 24.21 is Positive, neither overbought nor oversold. The STOCH value of 18.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TPST.
Tempest Therapeutics Risk Analysis
Tempest Therapeutics disclosed 78 risk factors in its most recent earnings report. Tempest Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksTempest Therapeutics Peers Comparison
Overall Rating
ATNM65.75Neutral
LTRN42Neutral
PDSB42Neutral
TPST41Neutral
CALC39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 66Neutral | $46.85M | 4.19 | 83.42% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | $5.81M | -0.26 | -456.35% | ― | ― | 9.68% | |
| 42Neutral | $97.04M | -1.63 | -0.96% | ― | ― | 32.24% | |
| 41Neutral | $6.83M | -0.09 | -3552.74% | ― | ― | 61.31% | |
| 39Underperform | $8.21M | -0.25 | -3029.57% | ― | ― | 45.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TPST | Tempest Therapeutics, Inc. | 0.34 | -4.41 | -92.82% | |
| ATNM | Actinium Pharmaceuticals | 1.49 | 0.13 | 9.56% | |
| PDSB | Pds Biotechnology | 0.92 | 0.17 | 23.20% | |
| LTRN | Lantern Pharma, Inc. | 0.39 | -2.88 | -88.10% | |
| CALC | Calcimedica, Inc. | 1.19 | -14.59 | -92.46% |
Tempest Therapeutics Corporate Events
Tempest Therapeutics Adjourns Special Meeting Over Voting Proposal
NeutralOn November 12, 2026, Tempest Therapeutics adjourned its reconvened special meeting after a quorum was established with 11,052,422 shares, or 74.64% of the 14,806,997 outstanding shares, present or represented by proxy, but there were insufficient vo...
Tempest Therapeutics Exercises Rights to CD7 CAR-T Platform
PositiveOn November 11, 2026, Tempest Therapeutics exercised its option under a September 14, 2026 Exclusive Collaboration, Option and License Agreement with Hebei Senlang Biotechnology Co., Ltd. to obtain exclusive rights outside China to develop and commer...
Tempest Therapeutics Stockholders Approve Key Corporate Proposals
NeutralOn November 9, 2026, stockholders of Tempest Therapeutics elected John David Yee and William Drake Richey as Class II directors. They also ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year e...
Tempest Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice
NegativeOn November 4, 2026, Tempest Therapeutics received Nasdaq notice that its common stock had closed below $1 for 30 consecutive business days, breaching Nasdaq Listing Rule 5550(a)(2). The notice had no immediate effect on the stock’s Nasdaq listing or...
Tempest Therapeutics Announces CFO Resignation and Successor
NeutralOn October 26, 2026, Tempest Therapeutics announced that Chief Financial Officer Constance Ames resigned from all her positions at the company effective immediately, citing personal reasons unrelated to the business. On the same day, the board appoin...
Tempest Therapeutics Faces Setback on Governance Reforms
NegativeOn October 14, 2026, Tempest Therapeutics reconvened a special meeting of stockholders originally held on July 27, 2026, and previously adjourned on August 17 and September 15, to seek approval of an amendment removing certain supermajority voting re...
Tempest Therapeutics Adds Veteran Executive to Board
PositiveOn October 13, 2026, Tempest Therapeutics appointed veteran financial and operating executive John W. Frederick as a Class III director on its board, with his term running until the 2027 annual meeting of stockholders. As a non-employee director, Fre...
Tempest Therapeutics Strengthens Governance and CAR-T Partnership Framework
PositiveOn Sept. 22, 2026, Tempest Therapeutics entered into a Master Services Agreement with related-party Factor Bioscience Inc. to provide research and development services, including Work Order No. 1 for in vivo CAR-T therapy development, with expected f...
Tempest Therapeutics Expands In Vivo CAR-T Collaboration
PositiveOn September 14, 2026, Tempest Therapeutics entered an exclusive collaboration, option and license agreement with Hebei Senlang Biotechnology that grants Tempest a four-month exclusive option to license Senlang’s CD7-targeted lentiviral in vivo CAR-T...
Tempest Therapeutics Adjourns Meeting on Governance Changes
NegativeOn September 15, 2026, Tempest Therapeutics reconvened a special shareholder meeting originally held on July 27 and August 17, 2026, to seek approval for an amendment to its Restated Certificate of Incorporation that would replace certain supermajori...
Tempest Therapeutics Announces New Private Warrant Financing
PositiveOn September 11, 2026, Tempest Therapeutics entered into a securities purchase agreement with an institutional investor for a private placement of pre-funded warrants and Series C and D common stock warrants, raising approximately $2.5 million in gro...
Tempest Therapeutics Announces New Chief Financial Officer
NeutralOn August 18, 2026, Tempest Therapeutics, Inc. disclosed that Principal Financial Officer and Principal Accounting Officer Justin Trojanowski had resigned from all his roles at the company, with the departure scheduled to take effect on September 1,...
Tempest Therapeutics Adjourns Special Stockholder Meeting Again
NegativeOn August 17, 2026, Tempest Therapeutics reconvened a special meeting of stockholders originally convened and adjourned on July 27, 2026, to seek approval of an amendment to its Restated Certificate of Incorporation that would replace certain superma...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
